Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
The first phase II trial for the management of oesophageal cancer

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.12
Views: 6071

Prof David Ferry – New Cross Hospital, Wolverhampton, UK

Prof David Ferry talks to ecancer at the 2012 ESMO meeting in Vienna about the first randomised phase II clinical trial in metastatic oesophageal cancer.


Previously, after first line chemotherapy, which only provides an average of 10 months survival, no second line therapy could be offered. Between 1996-2011, only 55 phase II trials had been conducted for oesophageal cancer and just five trials resulting in response.


Prof Ferry and his team investigated gefitinib with 450 patients, but with results not meeting the primary goal of overall survival. However, secondary goals of increased progression free survival and quality of life in patient reported outcomes were reported.


Future studies from the data are already occurring in the translational setting with analysis of biopsy samples for potential biomarkers.


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation